Cargando…

A Case Report of Atezolizumab Induced Tumor Lysis Syndrome

Patient: Female, 67 Final Diagnosis: Atezolizumab induced tumor lysis syndrome Symptoms: Generalized weakness • hematuria • nausea • vomiting Medication: Atezolizumab Clinical Procedure: — Specialty: Oncology OBJECTIVE: Unusual clinical course BACKGROUND: Advanced urothelial carcinoma has been assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fa’ak, Faisal, Vanegas, Diego, Osei, Kofi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561135/
https://www.ncbi.nlm.nih.gov/pubmed/31160547
http://dx.doi.org/10.12659/AJCR.915351
_version_ 1783426089900572672
author Fa’ak, Faisal
Vanegas, Diego
Osei, Kofi M.
author_facet Fa’ak, Faisal
Vanegas, Diego
Osei, Kofi M.
author_sort Fa’ak, Faisal
collection PubMed
description Patient: Female, 67 Final Diagnosis: Atezolizumab induced tumor lysis syndrome Symptoms: Generalized weakness • hematuria • nausea • vomiting Medication: Atezolizumab Clinical Procedure: — Specialty: Oncology OBJECTIVE: Unusual clinical course BACKGROUND: Advanced urothelial carcinoma has been associated with poor prognosis due to high resistance to chemotherapy and radiation until immunotherapeutic agents, such as atezolizumab, emerged as an option and have shown improved survival. However, atezolizumab is associated with side effects, which were mainly autoimmune. In this case study, we report on a rare case of atezolizumab-induced tumor lysis syndrome. CASE REPORT: A 67-year-old female with a primary diagnosis of metastatic urothelial carcinoma who presented to the emergency department with generalized weakness associated with nausea and vomiting 8 days after her first cycle of atezolizumab. Laboratory values showed hyperphosphatemia, hyperuricemia, hypocalcemia, and acute kidney injury consistent with tumor lysis syndrome. CONCLUSIONS: In our report, we highlight tumor lysis syndrome as a potential reaction to atezolizumab; a condition that requires prophylaxis and close laboratory monitoring.
format Online
Article
Text
id pubmed-6561135
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-65611352019-06-26 A Case Report of Atezolizumab Induced Tumor Lysis Syndrome Fa’ak, Faisal Vanegas, Diego Osei, Kofi M. Am J Case Rep Articles Patient: Female, 67 Final Diagnosis: Atezolizumab induced tumor lysis syndrome Symptoms: Generalized weakness • hematuria • nausea • vomiting Medication: Atezolizumab Clinical Procedure: — Specialty: Oncology OBJECTIVE: Unusual clinical course BACKGROUND: Advanced urothelial carcinoma has been associated with poor prognosis due to high resistance to chemotherapy and radiation until immunotherapeutic agents, such as atezolizumab, emerged as an option and have shown improved survival. However, atezolizumab is associated with side effects, which were mainly autoimmune. In this case study, we report on a rare case of atezolizumab-induced tumor lysis syndrome. CASE REPORT: A 67-year-old female with a primary diagnosis of metastatic urothelial carcinoma who presented to the emergency department with generalized weakness associated with nausea and vomiting 8 days after her first cycle of atezolizumab. Laboratory values showed hyperphosphatemia, hyperuricemia, hypocalcemia, and acute kidney injury consistent with tumor lysis syndrome. CONCLUSIONS: In our report, we highlight tumor lysis syndrome as a potential reaction to atezolizumab; a condition that requires prophylaxis and close laboratory monitoring. International Scientific Literature, Inc. 2019-06-04 /pmc/articles/PMC6561135/ /pubmed/31160547 http://dx.doi.org/10.12659/AJCR.915351 Text en © Am J Case Rep, 2019 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Fa’ak, Faisal
Vanegas, Diego
Osei, Kofi M.
A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
title A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
title_full A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
title_fullStr A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
title_full_unstemmed A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
title_short A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
title_sort case report of atezolizumab induced tumor lysis syndrome
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561135/
https://www.ncbi.nlm.nih.gov/pubmed/31160547
http://dx.doi.org/10.12659/AJCR.915351
work_keys_str_mv AT faakfaisal acasereportofatezolizumabinducedtumorlysissyndrome
AT vanegasdiego acasereportofatezolizumabinducedtumorlysissyndrome
AT oseikofim acasereportofatezolizumabinducedtumorlysissyndrome
AT faakfaisal casereportofatezolizumabinducedtumorlysissyndrome
AT vanegasdiego casereportofatezolizumabinducedtumorlysissyndrome
AT oseikofim casereportofatezolizumabinducedtumorlysissyndrome